Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ZYXI

Zynex Inc

Sep 20 • 04:00PM ET

8.12

Dollar change -0.21
Percentage change -2.52	%

Healthcare • Medical Distribution • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO FSMD IWC JPSE AVSC BFOR

Index	RUT	P/E	46.83	EPS (ttm)	0.17	Insider Own	46.55%	Shs Outstand	32.93M	Perf Week	-0.37%
Market Cap	257.73M	Forward P/E	15.72	EPS next Y	0.52	Insider Trans	-0.22%	Shs Float	16.97M	Perf Month	5.05%
Income	6.04M	PEG	-	EPS next Q	0.06	Inst Own	29.82%	Short Float	32.34%	Perf Quarter	-9.78%
Sales	193.61M	P/S	1.33	EPS this Y	-22.22%	Inst Trans	-3.25%	Short Ratio	36.46	Perf Half Y	-36.91%
Book/sh	1.03	P/B	7.85	EPS next Y	146.03%	ROA	4.40%	Short Interest	5.49M	Perf Year	1.12%
Cash/sh	0.97	P/C	8.34	EPS next 5Y	-	ROE	12.70%	52W Range	7.04 - 13.77	Perf YTD	-25.44%
Dividend Est.	-	P/FCF	14.84	EPS past 5Y	1.09%	ROI	5.82%	52W High	-41.03%	Beta	0.54
Dividend TTM	-	Quick Ratio	3.22	Sales past 5Y	43.84%	Gross Margin	79.81%	52W Low	15.34%	ATR (14)	0.34
Dividend Ex-Date	Jan 05, 2022	Current Ratio	4.06	EPS Y/Y TTM	-61.99%	Oper. Margin	5.44%	RSI (14)	50.84	Volatility	4.85% 3.65%
Employees	1100	Debt/Eq	2.28	Sales Y/Y TTM	9.11%	Profit Margin	3.12%	Recom	1.00	Target Price	17.50
Option/Short	Yes / Yes	LT Debt/Eq	2.16	EPS Q/Q	-58.23%	Payout	0.00%	Rel Volume	2.14	Prev Close	8.33
Sales Surprise	-4.06%	EPS Surprise	-47.85%	Sales Q/Q	10.97%	Earnings	Jul 25 AMC	Avg Volume	150.51K	Price	8.12
SMA20	1.47%	SMA50	-3.46%	SMA200	-21.58%	Trades		Volume	322,447	Change	-2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-23	Initiated	RBC Capital Mkts	Outperform	$13
Jan-06-23	Upgrade	Piper Sandler	Neutral → Overweight	$10 → $18
Feb-28-22	Reiterated	B. Riley Securities	Buy	$15.50 → $10
Jul-16-21	Upgrade	B. Riley Securities	Neutral → Buy	$19.50
Jul-16-21	Upgrade	B. Riley Securities	Neutral → Buy	$19 → $19.50
Mar-09-21	Upgrade	Northland Capital	Market Perform → Outperform	$22.50
Feb-26-21	Downgrade	B. Riley Securities	Buy → Neutral	$19
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral	$28 → $20
Jan-28-21	Downgrade	Northland Capital	Outperform → Market Perform	$22.50
Sep-14-20	Upgrade	H.C. Wainwright	Neutral → Buy	$25
Sep-09-20	Upgrade	Northland Capital	Market Perform → Outperform	$22.50
Jul-29-20	Upgrade	B. Riley FBR	Neutral → Buy	$28
Jul-20-20	Initiated	Piper Sandler	Overweight	$30
Jul-13-20	Downgrade	B. Riley FBR	Buy → Neutral
Jul-10-20	Reiterated	H.C. Wainwright	Neutral	$20 → $30
Jun-16-20	Downgrade	Northland Capital	Outperform → Market Perform
May-19-20	Downgrade	H.C. Wainwright	Buy → Neutral	$20
Apr-01-20	Initiated	Northland Capital	Outperform	$15
Sep-23-19	Initiated	H.C. Wainwright	Buy	$12

Show Previous Ratings

Sep-04-24 09:53AM	FDA clears Zynexs TensWave device for pain management (Medical Device Network)
09:15AM	Zynex to Present at the HC Wainwright Global Investment Conference (PR Newswire)
Sep-03-24 09:15AM	Zynex Obtains FDA clearance for new Pain Management Device (PR Newswire)
Aug-09-24 01:02AM	Insider Sale: COO Anna Lucsok Sells 24,875 Shares of Zynex Inc (ZYXI) (GuruFocus.com)
Jul-31-24 09:42AM	Zynex Inc. CEO Thomas Sandgaard Discusses Significant Company Growth and Future Innovations (News Direct) +9.49%
04:37PM	Loading…
Jul-26-24 04:37PM	Why Zynex Plunged Today (Motley Fool) -12.37% -6.61%
12:34PM	Q2 2024 Zynex Inc Earnings Call (Thomson Reuters StreetEvents)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-25-24 05:35PM	Zynex Inc. (ZYXI) Q2 Earnings and Revenues Lag Estimates (Zacks)
04:01PM	Zynex Reports Second Quarter 2024 Financial Results (PR Newswire)
Jul-17-24 09:15AM	Zynex Sets Second Quarter 2024 Earnings Call (PR Newswire)
Jul-11-24 09:15AM	Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces (PR Newswire)
Jun-26-24 12:00PM	All You Need to Know About Zynex (ZYXI) Rating Upgrade to Buy (Zacks)
Jun-24-24 06:00AM	3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally (InvestorPlace)
Jun-19-24 06:00AM	Analyst Predictions: 3 Stocks Pegged to Soar Over 40% in One Year (InvestorPlace)
09:40AM	Loading…
Jun-12-24 09:40AM	Is Zynex (ZYXI) Stock Undervalued Right Now? (Zacks)
Jun-10-24 09:30AM	Zynex to Participate in Fireside Chat with RBC Capital Markets on Thursday, June 13, 2024 (PR Newswire)
May-27-24 09:40AM	Should Value Investors Buy Zynex (ZYXI) Stock? (Zacks)
May-23-24 12:45PM	Zynex (ZYXI) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
May-09-24 09:40AM	Are Investors Undervaluing Zynex (ZYXI) Right Now? (Zacks)
09:15AM	Zynex to Present at the RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-07-24 12:45PM	3 Reasons Growth Investors Will Love Zynex (ZYXI) (Zacks)
09:15AM	Zynex Executives Recognized Among Top 25 in Medical Technology (PR Newswire)
May-02-24 08:55AM	Zynex, Inc. (NASDAQ:ZYXI) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:01AM	Zynex Inc (ZYXI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Seizing ... (GuruFocus.com)
Apr-30-24 08:58PM	ZYXI Stock Earnings: Zynex Misses Revenue for Q1 2024 (InvestorPlace) +7.29%
05:44PM	Zynex Inc (ZYXI) Q1 2024 Earnings: Revenue Meets Expectations, EPS Falls Short (GuruFocus.com)
04:01PM	Zynex Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-18-24 09:15AM	Zynex Sets First Quarter 2024 Earnings Call (PR Newswire) -5.14%
Apr-02-24 02:58PM	3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation? (InvestorPlace)
09:15AM	Loading…
09:15AM	Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award (PR Newswire)
Mar-02-24 08:43AM	Zynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 12:05PM	Zynex Price Target Raised by RBC Capital, HC Wainwright Analysts (Exec Edge) -9.29%
Feb-29-24 05:20PM	Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates (Zacks)
04:39PM	Zynex Inc (ZYXI) Reports 17% Revenue Growth in FY 2023, Announces New $20 Million Stock ... (GuruFocus.com)
04:01PM	Zynex Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-22-24 09:15AM	Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call (PR Newswire)
Feb-20-24 09:15AM	Zynex Introduces New Products (PR Newswire)
Feb-08-24 09:00AM	Sichenzia Ross Ference Carmel LLP Closes Over 100 Capital Markets Transactions Valued At Over $700 Million in 2023 (GlobeNewswire)
Feb-06-24 09:15AM	Zynex Receives FDA Clearance for its Next Generation NMES Device (PR Newswire)
Feb-02-24 09:15AM	Zynex Recognized in Top 25 Medical Device Companies for 2024 (PR Newswire)
Jan-28-24 01:27PM	3 Unloved Growth Stocks Poised for a Major Turnaround (InvestorPlace)
Jan-08-24 09:15AM	Zynex to Participate at the Needham Annual Growth Conference (PR Newswire)
Dec-15-23 01:10PM	Full Video Coverage Healthcare Trends, Financing, Future Directions in 2024 Panel at 3rd Palm Beach CorpGov Forum (CorpGov.com)
Dec-08-23 10:13AM	12 Best Healthcare Stocks For the Long-Term (Insider Monkey)
Nov-27-23 02:08PM	Healthcare Edge: Trends, Financing, Future Directions in 2024 Panel at 3rd Palm Beach CorpGov Forum (Exec Edge)
Nov-15-23 09:15AM	Zynex Ranked in Forbes List of 'America's Most Successful Small-Cap Companies 2024' (PR Newswire)
Nov-13-23 09:15AM	Zynex Submits FDA Application for its Next Generation NMES Device (PR Newswire)
Nov-09-23 09:15AM	Zynex Named as a Winner in the Deloitte 2023 Technology Fast 500 Awards for the 5th Consecutive Year (PR Newswire)
Nov-01-23 10:30AM	EXCLUSIVE: Medical Devices Firm Zynex Launches New $20M Share Repurchase Program (Benzinga)
09:15AM	Zynex Announces Share Repurchase Program (PR Newswire)
Oct-31-23 06:45AM	Zynex Announces Review of Strategic Alternatives (PR Newswire)
Oct-27-23 11:05AM	Q3 2023 Zynex Inc Earnings Call (Thomson Reuters StreetEvents) +16.64%
10:17AM	Zynex, Inc. (NASDAQ:ZYXI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 06:09PM	Zynex Inc (ZYXI) Q3 2023 Earnings: Revenue Up 20% to $49.9 Million, EPS at $0.10 (GuruFocus.com)
05:15PM	Zynex Inc. (ZYXI) Q3 Earnings Match Estimates (Zacks)
04:01PM	Zynex Reports Third Quarter 2023 Financial Results (PR Newswire)
02:33PM	Zynex makes Healthcare Technology Reports Top 100 healthcare tech companies for 2nd straight year (News Direct)
Oct-19-23 11:28AM	Zynex Ranks 23rd Among Top 100 Healthcare Technology Companies (Exec Edge) -8.37%
09:15AM	Zynex Recognized in Top 100 Healthcare Technologies Companies for Second Year in a Row (PR Newswire)
Oct-12-23 09:15AM	Zynex, Inc Sets Third Quarter 2023 Earnings Call (PR Newswire)
Oct-06-23 09:00AM	3 Micro-Cap Stocks to Sell While You Still Can (InvestorPlace)
Sep-19-23 09:15AM	Zynex to Present at the Cantor Global Healthcare Conference (PR Newswire)
Sep-11-23 09:15AM	Zynex Announces Share Repurchase Program (PR Newswire) +8.25%
Sep-05-23 09:15AM	Zynex to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) -6.16%
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Aug-10-23 09:15AM	Zynex Announces 1 Millionth Patient Milestone (PR Newswire)
Aug-09-23 09:15AM	Zynex, Inc Announces New Therapy Products (PR Newswire)
Aug-03-23 09:15AM	Zynex, Inc Founder and CEO Thomas Sandgaard to participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar on August 3rd at 12:15 PM ET (PR Newswire)
Jul-28-23 05:53AM	Q2 2023 Zynex Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-27-23 05:25PM	Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:01PM	Zynex Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-24-23 08:25AM	Zynex, Inc.'s (NASDAQ:ZYXI) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? (Simply Wall St.)
Jul-20-23 09:15AM	Zynex, Inc. Sets Second Quarter 2023 Earnings Call (PR Newswire)
Jul-17-23 09:15AM	Zynex, Inc. (NASD: ZYXI) Wins 2023 National Top Workplaces Award in the Manufacturing Industry Category (PR Newswire)
Jul-12-23 09:15AM	Zynex Reports Preliminary Second Quarter 2023 Results (PR Newswire)
Jul-10-23 09:15AM	Zynex, Inc. Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program (PR Newswire)
Jun-21-23 08:00PM	ZYXI: What does Argus have to say about ZYXI? (Argus Research)
Jun-20-23 09:15AM	Zynex Receives FDA Clearance of CM-1600 Monitor for Improved Blood and Fluid Management (PR Newswire)
Jun-14-23 12:33PM	Why Shares of Zynex Are Up Wednesday (Motley Fool) +10.21%
09:15AM	Zynex Announces Share Buyback Program (PR Newswire)
May-30-23 06:34PM	7 Stocks With 1,000% Upside Potential (InvestorPlace)
May-29-23 02:20PM	Those who invested in Zynex (NASDAQ:ZYXI) five years ago are up 214% (Simply Wall St.)
May-05-23 12:17PM	After the recent decline, Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard's holdings have lost 17% of their value (Simply Wall St.)
May-04-23 09:04PM	Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering (PR Newswire) -35.65%
07:30AM	Zynex Announces Update Regarding Previously Announced Offerings (PR Newswire)
May-03-23 04:02PM	Zynex Announces Proposed Secondary Public Offering of Common Stock (PR Newswire)
04:01PM	Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes (PR Newswire)
09:15AM	Zynex Named as a Winner of Colorado's Top Workplaces 2023 by The Denver Post (PR Newswire)
Apr-27-23 05:45PM	Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	Zynex Announces 2023 First Quarter Earnings (PR Newswire)
Apr-26-23 08:00PM	ZYXI: Lowering target price to $12.00 (Argus Research)
Apr-20-23 01:42PM	7 Small-Cap Stocks With Big Potential (InvestorPlace)
Apr-19-23 09:15AM	Zynex, Inc. to Announce First Quarter 2023 Financial Results (PR Newswire)
Apr-13-23 07:22AM	An Intrinsic Calculation For Zynex, Inc. (NASDAQ:ZYXI) Suggests It's 44% Undervalued (Simply Wall St.)
Apr-11-23 09:15AM	Zynex Reports Preliminary First Quarter 2023 Results (PR Newswire)
Apr-06-23 09:15AM	Zynex Earns Spot on Financial Times List of "The Americas' Fastest-Growing Companies 2023" for Second Consecutive Year (PR Newswire)
Mar-21-23 09:15AM	Zynex Included in Denver-Area's Top 10 Biotechnology/Bioscience Companies (PR Newswire) +6.01%
Mar-15-23 05:42PM	Zynex, Inc. (NASDAQ:ZYXI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-13-23 10:17PM	Q4 2022 Zynex Inc Earnings Call (Thomson Reuters StreetEvents) +14.80%

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lucsok Anna	CHIEF OPERATING OFFICER	Aug 06 '24	Sale	8.01	16,792	134,504	25,063	Aug 08 07:05 PM
Lucsok Anna	CHIEF OPERATING OFFICER	Aug 07 '24	Sale	8.03	8,083	64,906	16,980	Aug 08 07:05 PM
Disbrow Joshua R.	Director	Jul 29 '24	Buy	8.32	7,000	58,233	72,000	Jul 30 06:25 PM
MOORHEAD DANIEL J	CHIEF FINANCIAL OFFICER	Jul 30 '24	Sale	8.24	15,000	123,600	46,571	Jul 30 06:23 PM
Daniel Moorhead	Officer	Jul 30 '24	Proposed Sale	8.34	15,000	125,100		Jul 30 09:00 AM
Sandgaard Thomas	PRESIDENT, CEO AND CHAIRMAN	Oct 16 '23	Option Exercise	0.20	209,000	41,800	14,604,465	Oct 17 07:02 PM

Dollar change +0.05
Percentage change 2.08	%

AYTU Aytu BioPharma Inc daily Stock Chart

Held by: VXF DFAT DFAC

Index	-	P/E	-	EPS (ttm)	-2.64	Insider Own	3.41%	Shs Outstand	5.97M	Perf Week	-5.04%
Market Cap	14.63M	Forward P/E	3.77	EPS next Y	0.65	Insider Trans	0.00%	Shs Float	5.77M	Perf Month	-8.92%
Income	-13.68M	PEG	-	EPS next Q	-0.45	Inst Own	34.39%	Short Float	5.62%	Perf Quarter	-15.81%
Sales	93.76M	P/S	0.16	EPS this Y	51.27%	Inst Trans	-	Short Ratio	18.78	Perf Half Y	-17.79%
Book/sh	5.53	P/B	0.44	EPS next Y	126.10%	ROA	-9.91%	Short Interest	0.32M	Perf Year	54.57%
Cash/sh	3.31	P/C	0.74	EPS next 5Y	-	ROE	-38.18%	52W Range	1.53 - 3.50	Perf YTD	-13.73%
Dividend Est.	-	P/FCF	1.69	EPS past 5Y	72.18%	ROI	-37.42%	52W High	-30.00%	Beta	-1.43
Dividend TTM	-	Quick Ratio	0.69	Sales past 5Y	118.34%	Gross Margin	59.88%	52W Low	60.58%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	0.85	EPS Y/Y TTM	95.63%	Oper. Margin	1.55%	RSI (14)	45.48	Volatility	6.85% 5.09%
Employees	150	Debt/Eq	1.03	Sales Y/Y TTM	-9.95%	Profit Margin	-14.60%	Recom	1.00	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.19	EPS Q/Q	73.00%	Payout	-	Rel Volume	1.86	Prev Close	2.40
Sales Surprise	3.73%	EPS Surprise	18.75%	Sales Q/Q	-20.85%	Earnings	May 15 AMC	Avg Volume	17.25K	Price	2.45
SMA20	-0.33%	SMA50	-4.66%	SMA200	-13.26%	Trades		Volume	32,023	Change	2.08%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight	$11
May-29-20	Initiated	H.C. Wainwright	Buy	$3

Sep-19-24 05:30PM	Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 (ACCESSWIRE)
Aug-08-24 05:20PM	Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 (ACCESSWIRE)
Aug-06-24 08:00AM	Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations (ACCESSWIRE)
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
08:00AM	Loading…
Jun-18-24 08:00AM	Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms (ACCESSWIRE)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile)
May-23-24 09:00AM	Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (ACCESSWIRE)
May-16-24 09:53AM	Q3 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Aytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ... (GuruFocus.com)
May-15-24 08:54PM	AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024 (InvestorPlace) -7.83%
04:05PM	Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results (ACCESSWIRE)
May-08-24 04:15PM	Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 (ACCESSWIRE)
Apr-03-24 09:00AM	Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
07:00AM	Loading…
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Feb-16-24 08:27AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-15-24 05:49AM	Q2 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-14-24 04:05PM	Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter (ACCESSWIRE) +5.35%
Feb-07-24 04:15PM	Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 (ACCESSWIRE)
Jan-23-24 09:00AM	Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (ACCESSWIRE)
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-30-23 08:00AM	Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023 (ACCESSWIRE)
Nov-15-23 09:44AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript (Insider Monkey) -22.11%
Nov-14-23 04:05PM	Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results (ACCESSWIRE) +10.11%
Nov-08-23 08:30AM	Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year (ACCESSWIRE)
Nov-07-23 04:15PM	Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023 (ACCESSWIRE) +5.14%
Oct-26-23 08:00AM	Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement (ACCESSWIRE) +5.82%
Oct-09-23 04:15PM	Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023 (ACCESSWIRE) -8.59%
08:18AM	Loading…
Sep-28-23 08:18AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript (Insider Monkey) +39.06%
Sep-27-23 04:20PM	Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 (ACCESSWIRE) +16.36%
Sep-21-23 08:25PM	Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023 (ACCESSWIRE)
Sep-13-23 08:00AM	Aytu BioPharma to Present at LD Micro Main Event XVI Conference (ACCESSWIRE)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly) +10.30%
07:43AM	Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Jul-31-23 08:00AM	Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority (ACCESSWIRE)
Jul-10-23 08:00AM	Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement (ACCESSWIRE) +5.36%
Jun-14-23 08:00AM	Aytu to Participate in the Maxim Group Virtual Healthcare Conference (ACCESSWIRE)
Jun-13-23 01:45PM	Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market (ACCESSWIRE) +6.59%
Jun-09-23 08:00AM	Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director (ACCESSWIRE)
May-16-23 11:51AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 04:25PM	AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates (InvestorPlace) -13.21%
04:05PM	Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results (ACCESSWIRE)
May-04-23 04:30PM	Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023 (ACCESSWIRE)
May-01-23 08:00AM	Aytu BioPharma Subleases a Portion of Its Manufacturing Facility (ACCESSWIRE)
Apr-27-23 08:00AM	Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer (ACCESSWIRE)
Mar-06-23 09:55AM	Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Feb-23-23 04:33PM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Call Transcript (Insider Monkey) -5.78%
Feb-21-23 04:10PM	Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 (ACCESSWIRE) -5.78%
03:00PM	Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023 (ACCESSWIRE)
Feb-14-23 08:00AM	Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results (ACCESSWIRE)
Feb-07-23 08:00AM	Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023 (ACCESSWIRE)
Feb-06-23 10:57AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jan-25-23 08:00AM	Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance (ACCESSWIRE) -6.46%
Jan-24-23 08:00AM	Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31 (ACCESSWIRE)
Jan-10-23 08:00AM	Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients (ACCESSWIRE)
Jan-05-23 04:01PM	Aytu BioPharma Announces 1-for-20 Reverse Stock Split (ACCESSWIRE) +7.28% -10.27%
Dec-29-22 06:01AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript (Insider Monkey)
Nov-30-22 08:00AM	Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect (ACCESSWIRE)
Nov-22-22 04:05PM	Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (ACCESSWIRE) -13.51%
Nov-17-22 08:58AM	US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results (Simply Wall St.)
08:00AM	Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row (ACCESSWIRE)
Nov-16-22 08:00AM	Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso (ACCESSWIRE) +12.58%
05:59AM	Aytu BioPharma First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 04:05PM	Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 (ACCESSWIRE)
Nov-07-22 04:01PM	Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 (ACCESSWIRE)
Oct-25-22 08:00AM	Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan (ACCESSWIRE) +6.72%
Oct-13-22 10:57AM	Aytu BioPharma Announces Strategic Shift, Indefinite Suspension of Clinical Development Programs (Benzinga)
08:00AM	Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs (ACCESSWIRE)
Oct-05-22 08:00AM	Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions (ACCESSWIRE) -5.18%
Sep-27-22 04:30PM	Edited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue (ACCESSWIRE)
Sep-20-22 08:00AM	Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022 (ACCESSWIRE)
Sep-14-22 08:00AM	Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin (ACCESSWIRE)
Aug-24-22 08:00AM	Aytu BioPharma to Participate in September 2022 Investor Conferences (ACCESSWIRE)
Aug-16-22 08:00AM	Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin (ACCESSWIRE)
Aug-15-22 04:01PM	Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering (ACCESSWIRE)
Aug-09-22 09:15AM	Aytu BioPharma Announces Pricing of Public Offering (ACCESSWIRE) -51.67%
Aug-08-22 04:01PM	Aytu BioPharma Announces Launch of Public Offering (ACCESSWIRE)
Jul-26-22 08:00AM	Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference (ACCESSWIRE) -6.48%
Jul-20-22 08:00AM	Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome (ACCESSWIRE)
Jun-29-22 08:00AM	Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors (ACCESSWIRE)
Jun-13-22 08:00AM	Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference (ACCESSWIRE) -8.65%
May-17-22 07:29AM	Aytu BioPharma Plans To Divest / Discontinue Non Core Assets (Benzinga) +13.05%
May-16-22 04:02PM	Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities (ACCESSWIRE) -5.85%
Apr-25-22 08:00AM	Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology (ACCESSWIRE)
Apr-19-22 08:00AM	Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome (ACCESSWIRE) -12.68%
Mar-23-22 08:00AM	Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R) (ACCESSWIRE)
Mar-22-22 08:00AM	Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit (ACCESSWIRE)
Mar-08-22 08:00AM	Aytu BioPharma to Participate in the 34th Annual Roth Conference (ACCESSWIRE)
Mar-07-22 04:05PM	Aytu BioPharma Announces Closing of $7.6 Million Registered Offering (ACCESSWIRE)
Mar-02-22 08:00PM	Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering (ACCESSWIRE) +5.74% -5.43%
08:00AM	Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome (ACCESSWIRE)
Feb-18-22 09:40AM	Has Aytu BioPharma Inc. (AYTU) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-14-22 04:05PM	Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results (ACCESSWIRE) +7.26%
Jan-31-22 08:00AM	Aytu BioPharma Completes $15 Million Debt Refinancing (ACCESSWIRE) +13.91%
Jan-04-22 08:00AM	Aytu BioPharma Appoints Mark Oki as Chief Financial Officer (ACCESSWIRE)
Jan-03-22 08:00AM	Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference (ACCESSWIRE) +14.81%

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

ZYXI

Zynex Inc

AYTU

Aytu BioPharma Inc

Upgrade your FINVIZ experience